How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The renin-angiotensin system (RAS) is related to the regulation of cell proliferation, angiogenesis, and tumor progression. Patients and Methods: We retrospectively analyzed the effect of angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) in 63 patients with advanced gastric cancer (AGC) with platinum-based chemotherapy. All patients analyzed had received medications for hypertension at the diagnosis of AGC. Patients were divided into two groups: an ACEI/ARB group (n = 30) and a non-ACEI/ARB group (n = 33). Results: Patient characteristics were not different between patients with and without ACEI/ARB. The response rate for all patients was 25.4% and the disease control rate was 77.8%. The median progression-free survival (PFS) for first-line chemotherapy was 5.5 months (95% CI 3.71-7.29) in the ACEI/ARB group and 4.3 months (95% CI 2.39-6.21) in the non-ACEI/ARB group (p = 0.506). There was a significant difference in overall survival (OS) in the ACEI/ARB group compared to the non-ACEI/ARB group (median OS: 8.2 vs. 13.9, p = 0.0095). In multivariate analysis, the use of ACEI/ARB was a significant independent prognostic factor for OS (p = 0.039) but not for PFS. Conclusion: ACEI/ARB in combination with standard chemotherapy might improve survival in patients with AGC and hypertension. These results support further investigation into the anticancer effects of ACEL/ARB.

Original languageEnglish
Pages (from-to)354-360
Number of pages7
JournalOncology (Switzerland)
Volume83
Issue number6
DOIs
Publication statusPublished - 2012 Oct 1

Fingerprint

Angiotensin II Type 1 Receptor Blockers
Renin-Angiotensin System
Platinum
Stomach Neoplasms
Drug Therapy
Angiotensin-Converting Enzyme Inhibitors
Enzyme Inhibitors
Survival
Disease-Free Survival
Hypertension
Multivariate Analysis
Cell Proliferation

Keywords

  • ACEI/ARB
  • Chemotherapy
  • Renin-angiotensin system

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{44b186b705334251ba57f2afb18f3bbc,
title = "How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?",
abstract = "Background: The renin-angiotensin system (RAS) is related to the regulation of cell proliferation, angiogenesis, and tumor progression. Patients and Methods: We retrospectively analyzed the effect of angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) in 63 patients with advanced gastric cancer (AGC) with platinum-based chemotherapy. All patients analyzed had received medications for hypertension at the diagnosis of AGC. Patients were divided into two groups: an ACEI/ARB group (n = 30) and a non-ACEI/ARB group (n = 33). Results: Patient characteristics were not different between patients with and without ACEI/ARB. The response rate for all patients was 25.4{\%} and the disease control rate was 77.8{\%}. The median progression-free survival (PFS) for first-line chemotherapy was 5.5 months (95{\%} CI 3.71-7.29) in the ACEI/ARB group and 4.3 months (95{\%} CI 2.39-6.21) in the non-ACEI/ARB group (p = 0.506). There was a significant difference in overall survival (OS) in the ACEI/ARB group compared to the non-ACEI/ARB group (median OS: 8.2 vs. 13.9, p = 0.0095). In multivariate analysis, the use of ACEI/ARB was a significant independent prognostic factor for OS (p = 0.039) but not for PFS. Conclusion: ACEI/ARB in combination with standard chemotherapy might improve survival in patients with AGC and hypertension. These results support further investigation into the anticancer effects of ACEL/ARB.",
keywords = "ACEI/ARB, Chemotherapy, Renin-angiotensin system",
author = "Kim, {Seung Tae} and Park, {Kyong Hwa} and Oh, {Sang Cheul} and Seo, {Jae Hong} and Kim, {Jun Suk} and Shin, {Sang Won} and Kim, {Yeul Hong}",
year = "2012",
month = "10",
day = "1",
doi = "10.1159/000337979",
language = "English",
volume = "83",
pages = "354--360",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "6",

}

TY - JOUR

T1 - How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?

AU - Kim, Seung Tae

AU - Park, Kyong Hwa

AU - Oh, Sang Cheul

AU - Seo, Jae Hong

AU - Kim, Jun Suk

AU - Shin, Sang Won

AU - Kim, Yeul Hong

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Background: The renin-angiotensin system (RAS) is related to the regulation of cell proliferation, angiogenesis, and tumor progression. Patients and Methods: We retrospectively analyzed the effect of angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) in 63 patients with advanced gastric cancer (AGC) with platinum-based chemotherapy. All patients analyzed had received medications for hypertension at the diagnosis of AGC. Patients were divided into two groups: an ACEI/ARB group (n = 30) and a non-ACEI/ARB group (n = 33). Results: Patient characteristics were not different between patients with and without ACEI/ARB. The response rate for all patients was 25.4% and the disease control rate was 77.8%. The median progression-free survival (PFS) for first-line chemotherapy was 5.5 months (95% CI 3.71-7.29) in the ACEI/ARB group and 4.3 months (95% CI 2.39-6.21) in the non-ACEI/ARB group (p = 0.506). There was a significant difference in overall survival (OS) in the ACEI/ARB group compared to the non-ACEI/ARB group (median OS: 8.2 vs. 13.9, p = 0.0095). In multivariate analysis, the use of ACEI/ARB was a significant independent prognostic factor for OS (p = 0.039) but not for PFS. Conclusion: ACEI/ARB in combination with standard chemotherapy might improve survival in patients with AGC and hypertension. These results support further investigation into the anticancer effects of ACEL/ARB.

AB - Background: The renin-angiotensin system (RAS) is related to the regulation of cell proliferation, angiogenesis, and tumor progression. Patients and Methods: We retrospectively analyzed the effect of angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) in 63 patients with advanced gastric cancer (AGC) with platinum-based chemotherapy. All patients analyzed had received medications for hypertension at the diagnosis of AGC. Patients were divided into two groups: an ACEI/ARB group (n = 30) and a non-ACEI/ARB group (n = 33). Results: Patient characteristics were not different between patients with and without ACEI/ARB. The response rate for all patients was 25.4% and the disease control rate was 77.8%. The median progression-free survival (PFS) for first-line chemotherapy was 5.5 months (95% CI 3.71-7.29) in the ACEI/ARB group and 4.3 months (95% CI 2.39-6.21) in the non-ACEI/ARB group (p = 0.506). There was a significant difference in overall survival (OS) in the ACEI/ARB group compared to the non-ACEI/ARB group (median OS: 8.2 vs. 13.9, p = 0.0095). In multivariate analysis, the use of ACEI/ARB was a significant independent prognostic factor for OS (p = 0.039) but not for PFS. Conclusion: ACEI/ARB in combination with standard chemotherapy might improve survival in patients with AGC and hypertension. These results support further investigation into the anticancer effects of ACEL/ARB.

KW - ACEI/ARB

KW - Chemotherapy

KW - Renin-angiotensin system

UR - http://www.scopus.com/inward/record.url?scp=84867225765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867225765&partnerID=8YFLogxK

U2 - 10.1159/000337979

DO - 10.1159/000337979

M3 - Article

C2 - 23052034

AN - SCOPUS:84867225765

VL - 83

SP - 354

EP - 360

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 6

ER -